{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:23:10Z","timestamp":1740147790647,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100016947","name":"Swim Across America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013041","name":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013041","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Convergence Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11912-022-01314-z","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T06:02:50Z","timestamp":1657000970000},"page":"1373-1375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is PD-1 Inhibitor Monotherapy a New Standard Treatment for MMR-Deficient Locally Advanced Rectal Cancer?"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-6083","authenticated-orcid":false,"given":"Eric S.","family":"Christenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"1314_CR1","doi-asserted-by":"publisher","unstructured":"van Gijn W, Marijnen CAM, Nagtegaal ID, Kranenbarg EM-K, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial [Internet]. Lancet Oncol. 2011. 575\u201382. https:\/\/doi.org\/10.1016\/s1470-2045(11)70097-3","DOI":"10.1016\/s1470-2045(11)70097-3"},{"key":"1314_CR2","doi-asserted-by":"publisher","first-page":"10953","DOI":"10.1038\/srep10953","volume":"5","author":"C Chen","year":"2015","unstructured":"Chen C, Sun P, Rong J, Weng H-W, Dai Q-S, Ye S. Short course radiation in the treatment of localized rectal cancer: a systematic review and meta-analysis. Sci Rep. 2015;5:10953.","journal-title":"Sci Rep"},{"key":"1314_CR3","doi-asserted-by":"publisher","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years [Internet]. J Clin Oncol. 2012. 1926\u201333. https:\/\/doi.org\/10.1200\/jco.2011.40.1836","DOI":"10.1200\/jco.2011.40.1836"},{"key":"1314_CR4","unstructured":"Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM-K, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. Elsevier; 2021;22:29\u201342."},{"key":"1314_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset J-F, Etienne P-L, Rio E, Fran\u00e7ois \u00c9, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol Elsevier. 2021;22:702\u201315.","journal-title":"Lancet Oncol Elsevier"},{"key":"1314_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, Jiang L-M, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681\u201392.","journal-title":"J Clin Oncol"},{"key":"1314_CR7","doi-asserted-by":"crossref","unstructured":"Rettig RL, Beard BW, Ryoo JJ, Kulkarni S, Gulati M, Tam M, Attaluri V. Total neoadjuvant therapy significantly increases complete clinical response. Dis Colon Rectum. 2022 [Online ahead of print]","DOI":"10.1097\/DCR.0000000000002290"},{"key":"1314_CR8","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim YK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022; [Online ahead of print]"},{"key":"1314_CR9","doi-asserted-by":"crossref","unstructured":"Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711\u20137; discussion 717\u20138.","DOI":"10.1097\/01.sla.0000141194.27992.32"},{"key":"1314_CR10","doi-asserted-by":"publisher","unstructured":"Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis [Internet]. Lancet Gastroenterol Hepatol. 2017. 501\u201313. https:\/\/doi.org\/10.1016\/s2468-1253(17)30074-2","DOI":"10.1016\/s2468-1253(17)30074-2"},{"key":"1314_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/SLA.0000000000003051","volume":"271","author":"S Hasan","year":"2020","unstructured":"Hasan S, Renz P, Wegner RE, Finley G, Raj M, Monga D, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) analysis. Ann Surg. 2020;271:716\u201323.","journal-title":"Ann Surg"},{"key":"1314_CR12","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/1078-0432.CCR-19-3728","volume":"26","author":"A Cercek","year":"2020","unstructured":"Cercek A, Dos Santos Fernandes G, Roxburgh CS, Ganesh K, Ng S, Sanchez-Vega F, et al. Mismatch repair\u2013deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res Am Assoc Cancer Res. 2020;26:3271\u20139.","journal-title":"Clin Cancer Res. Am Assoc Cancer Res"},{"key":"1314_CR13","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"1314_CR14","doi-asserted-by":"crossref","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022; [Online ahead of print]","DOI":"10.1056\/NEJMoa2201445"},{"key":"1314_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AA, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566\u201376.","journal-title":"Nat Med"},{"key":"1314_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/jnci\/djaa052","volume":"113","author":"K Ludford","year":"2021","unstructured":"Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, et al. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst. 2021;113:208\u201311.","journal-title":"J Natl Cancer Inst"},{"key":"1314_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/bjs\/znac050","volume":"109","author":"A Kothari","year":"2022","unstructured":"Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, et al. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient\/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg. 2022;109:489\u201392.","journal-title":"Br J Surg"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01314-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01314-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01314-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:40:58Z","timestamp":1666773658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01314-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01314-z","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"type":"print","value":"1523-3790"},{"type":"electronic","value":"1534-6269"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"23 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric Christenson receives compensation for consultation from Seres Therapeutics and has research collaborations with Haystack Oncology, Natera, Pfizer, and Veracyte. Jeffrey Meyer is a section editor for Current Oncology Reports. He receives royalties from Springer and UpToDate and has research collaborations with Boston Scientific.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}